Supplementary Online Content

Efficacy of intralesional botulinum toxin A for treatment of painful cutaneous leiomyomas: a randomized clinical trial.

eFigure. Daily Pain Diary

eTable 1. Leiomyoma Characteristics and Percent Change in Pain Scores

eTable 2. Participants Grouped by Percent Change in Pain Scores

This supplementary material has been provided by the authors to give readers additional information about their work.

Pain Diary Patient Self-Assessment

**Please complete this form at the same time each day. Please write name & dose of any pain meds taken each day.

Name.			
Date:	Time:	am/pm	
Answer the que	estion "My pain intensity	at this time is?" by marking the line.	
	No		Worst
	Pain		Possible Pain
	'		'
Pain meds used (Initial here	OR new meds started:		
Date:	Time:	am/pm	
Answer the que	estion "My pain intensity	at this time is?" by marking the line.	
	No		Worst
	Pain		Possible Pain
	ı		
Dain made usad (OP new made started:		
Initial here			
Date:	Time:	am/pm	
Answer the que	estion "My pain intensity	at this time is?" by marking the line.	
, morror and que		at the time is an arming the line.	l Mana
	No Pain		Worst Possible
			Pain
Traibial lague			
Initial here			
Date:	Time:	am/pm	
Answer the que	estion "My pain intensity	at this time is?" by marking the line.	
	No Pain		Worst Possible
			Pain
Pain meds used	OR new meds started:		
Initial here	OK NEW Meds started		

eTable 1. Leiomyoma Characteristics and Percent Change in Pain Scores. *BTX*, botulinum toxin-A treatment arm; *PBO*, placebo treatment arm; *VAS*, visual analog scale

Subject	Treatment Group	Total Injected Volume (ml)	Leimyoma Characteristics	Week 0 Pre-ice Pain VAS Score	Week 4 Pre-ice Pain VAS Score	% change in Pre-ice Pain VAS scores	Week 0 Post-ice Pain VAS Score	Week 4 Post-ice Pain VAS Score	% change in Post-ice Pain VAS Scores	Week 0 Average Lesional Pain	Week 4 Average Lesional Pain	% change in Average Pain Scores
1	BTX	6	6x11cm segmental	6.3	5.7	-9.5	10	9.5	-5.0	6	7	16.7
2	РВО	1.8	6x8cm segmental	0.2	1.0	400.0	7.7	4.6	-40.3	6	not collected	-
3	BTX	0.3	4 discrete papules	1.4	1	-28.6	7.4	8.1	9.5	4	4	0.0
4	РВО	0.55	8 discrete papules on trunk/extremities	0.1	0.7	600.0	1.1	6.8	518.2	1	1	0.0
5	втх	1.15	15 discrete papules on trunk/extremities	0.3	0.2	-33.3	5.1	3.5	-31.4	6	1	-83.3
6	РВО	3.1	10x11cm segmental	0.5	2.2	340.0	9.2	7.6	-17.4	4	5	25.0
7	BTX	1.5	4.5x7cm segmental	0	0	-	5.2	1.6	-69.2	0	0	-
8	PBO	0.1	3 discrete papules	1.6	0.3	-81.3	6.8	0.1	-98.5	1	4	300.0
9	РВО	0.14	4x6cm segmental, 3 discrete papules	2.1	2.2	4.8	7.5	6.7	-10.7	4	4	0.0
10	BTX	1	4x9cm segmental	0	0.8	-	7.1	3.7	-47.9	3	1	-66.7
11	PBO	2.6	4x6cm segmental	0	0	-	1.5	0.5	-66.7	1	1	0.0
12	BTX	5.9	6x10cm segmental	0	0	-	0.8	1	25.0	5	7	40.0
13	BTX	2.4	9.5x18cm segmental	3.3	0.1	-97.0	3.2	0.4	-87.5	5	0	-100.0
14	PBO	1.2	3.5x5cm segmental	0.1	1.3	1200.0	5.9	7.8	32.2	5	3	-40.0
15	втх	1.65	3.6x7.4cm segmental	1.2	1.6	33.3	9.4	8.7	-7.4	4	4	0.0
16	РВО	0.5	20x22cm segmental	0.1	0.1	0.0	2.7	2.1	-22.2	6	1	-83.3
17	втх	1.8	6.8x7.5cm segmental	3.1	0	-100.0	6.7	0.3	-95.5	8	2	-75.0
18	РВО	0.1	0.6x0.8cm solitary papule	0	0.4	-	4.3	0.3	-93.0	6	1	-83.3

eTable 2. Participants Grouped by Percent Change in Pain Scores. A. Percent change in average pain scores. B. Percent change in pre-ice VAS pain scores. C. Percent change in post-ice pain VAS scores. *BTX*, botulinum toxin-A treatment arm; *PBO*, placebo treatment arm; *VAS*, visual analog scale.

Α

% Change in Average Pain Score	BTX	PBO
>50% pain reduction	4 (44%)	2 (22%)
≤50% pain reduction	0 (0%)	1 (11%)
No change in pain	2 (22%)	3 (33%)
Increased pain	2 (22%)	2 (22%)
Missing	1 (11%)	1 (11%)
Total	9	9

В

% Change in Pre-Ice VAS Score	BTX	PBO
>50% pain reduction	2 (22%)	1 (11%)
≤50% pain reduction	3 (33%)	0 (0%)
No change in pain	0 (0%)	1 (11%)
Increased pain	1 (11%)	5 (55%)
Missing	3 (33%)	2 (22%)
Total	9	9

С

C		
% Change in Post-Ice VAS Score	BTX	PBO
>50% pain reduction	3 (33%)	3 (33%)
≤50% pain reduction	4 (44%)	4 (44%)
No change in pain	0 (0%)	0 (0%)
Increased pain	2 (22%)	2 (22%)
Missing	0 (0%)	0 (0%)
Total	9	9